ReviewFrontiers in cell and developmental biology2026
Musculoskeletal disorders: does cuproptosis hold the key?
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis, a recently identified form of programmed cell death, is triggered by intracellular copper accumulation and executed through mitochondrial metabolic interference and proteostasis disruption. While emerging evidence has elucidated its pathophysiological roles in oncology, neurodegenerative disorders, and metabolic diseases, its mechanistic involvement and therapeutic potential in musculoskeletal disorders-including osteoarthritis, rheumatoid arthritis, osteoporosis, intervertebral disc degeneration, ankylosing spondylitis, bone tumors, skeletal muscle atrophy, and osteonecrosis of the femoral head (ONFH)-remain largely unexplored. This comprehensive review synthesizes current knowledge on the molecular mechanisms underlying cuproptosis in musculoskeletal pathophysiology, its potential as a disease-modifying factor, and the translational challenges that must be addressed before its clinical application. Furthermore, we highlight critical knowledge gaps and propose novel research directions that may help advance this emerging field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.